Literature DB >> 25407874

Intensity modulated stereotactic body radiation therapy for single or multiple vertebral metastases with spinal cord compression.

Taro Murai1, Rumi Murata2, Yoshihiko Manabe3, Chikao Sugie3, Takeshi Tamura2, Hiroya Ito2, Yoshihito Miyoshi2, Yuta Shibamoto3.   

Abstract

PURPOSE: The purpose of this study was to evaluate the efficacy and toxicity of intensity modulated radiation therapy with simultaneous integrated boost (SIB-IMRT) for single or multiple vertebral metastases (VM) with spinal cord compression using tomotherapy. METHODS AND MATERIALS: Thirty patients with 40 VM were treated with SIB-IMRT as initial radiation therapy. Either 40 Gy in 8 fractions or 48 Gy in 16 fractions was prescribed depending on the Katagiri prognostic index. The radiation doses to the spinal cord and other risk organs were reduced to tolerance levels using intensity modulation. One to 4 lesions in consecutive vertebrae were treated in 1 course of SIB-IMRT. Radiologic and physical examinations were performed at 1-3 month intervals after SIB-IMRT. The Barthel index (BI) and numerical rating scale (NRS) were used to evaluate activities of daily living (ADL) and pain status, respectively.
RESULTS: The median follow-up period was 8 months. The NRS significantly dropped at 1 month after SIB-IMRT (P < .0001) and the effect continued for over 2 months. No significant BI decrease was observed at 2 months after SIB-IMRT (P = .7). The 1-year local control rate was 84% (95% confidence interval, 70%-100%). No grade≥2 neurologic toxicity resulting from SIB-IMRT was observed.
CONCLUSIONS: SIB-IMRT could be successfully applied to VM with spinal cord compression in up to 4 consecutive vertebrae. Good ADL preservation and pain control were achieved with acceptable toxicity.

Entities:  

Mesh:

Year:  2014        PMID: 25407874     DOI: 10.1016/j.prro.2014.02.005

Source DB:  PubMed          Journal:  Pract Radiat Oncol        ISSN: 1879-8500


  5 in total

1.  Tetrahydrocurcumin protects against spinal cord injury and inhibits the oxidative stress response by regulating FOXO4 in model rats.

Authors:  Jiancheng Xi; Xiaobo Luo; Yipeng Wang; Jinglong Li; Lixin Guo; Guangseng Wu; Qingui Li
Journal:  Exp Ther Med       Date:  2019-09-05       Impact factor: 2.447

2.  Efficacy of stereotactic radiotherapy for brain metastases using dynamic jaws technology in the helical tomotherapy system.

Authors:  Taro Murai; Akihiro Hayashi; Yoshihiko Manabe; Chikao Sugie; Taiki Takaoka; Takeshi Yanagi; Tetsuya Oguri; Masayuki Matsuo; Yoshimasa Mori; Yuta Shibamoto
Journal:  Br J Radiol       Date:  2016-08-24       Impact factor: 3.039

3.  Intensity-modulated radiotherapy with integrated-boost in patients with bone metastasis of the spine: study protocol for a randomized controlled trial.

Authors:  Tanja Sprave; Stefan Ezechiel Welte; Thomas Bruckner; Robert Förster; Tilman Bostel; Ingmar Schlampp; Nils Henrik Nicolay; Jürgen Debus; Harald Rief
Journal:  Trials       Date:  2018-01-22       Impact factor: 2.279

4.  Pain REduction with bone metastases STereotactic radiotherapy (PREST): A phase III randomized multicentric trial.

Authors:  Francesco Cellini; Stefania Manfrida; Francesco Deodato; Savino Cilla; Ernesto Maranzano; Stefano Pergolizzi; Fabio Arcidiacono; Rossella Di Franco; Francesco Pastore; Matteo Muto; Valentina Borzillo; Costanza Maria Donati; Giambattista Siepe; Salvatore Parisi; Antonia Salatino; Antonino D'Agostino; Giampaolo Montesi; Anna Santacaterina; Vincenzo Fusco; Mario Santarelli; Maria Antonietta Gambacorta; Renzo Corvò; Alessio Giuseppe Morganti; Valeria Masiello; Paolo Muto; Vincenzo Valentini
Journal:  Trials       Date:  2019-10-28       Impact factor: 2.279

5.  Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost in Patients With Spinal Metastases.

Authors:  Antonio Pontoriero; Giuseppe Iatì; Alberto Cacciola; Alfredo Conti; Anna Brogna; Carmelo Siragusa; Gianluca Ferini; Valerio Davì; Consuelo Tamburella; Laura Molino; Domenico Cambareri; Cesare Severo; Silvana Parisi; Nicola Settineri; Isidora Ielo; Stefano Pergolizzi
Journal:  Technol Cancer Res Treat       Date:  2020 Jan-Dec
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.